Guideline for Postmarketing Reporting of Adverse Drug Experiences March 1992
- Docket Number:
- Issued by:
Guidance Issuing OfficeCenter for Drug Evaluation and Research
The FDA published Good Guidance Practice in February 1997. This guidance was developed and issued prior to that date.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-1985-D-0044.